These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 29262741)
1. Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU. Samson AAS; Park S; Kim SY; Min DH; Jeon NL; Song JM J Liposome Res; 2019 Mar; 29(1):44-52. PubMed ID: 29262741 [TBL] [Abstract][Full Text] [Related]
2. Knockdown of clusterin alters mitochondrial dynamics, facilitates necrosis in camptothecin-induced cancer stem cells. Arumugam P; Samson A; Ki J; Song JM Cell Biol Toxicol; 2017 Jun; 33(3):307-321. PubMed ID: 28064403 [TBL] [Abstract][Full Text] [Related]
3. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes. Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847 [TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes. Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333 [TBL] [Abstract][Full Text] [Related]
5. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. Xue HY; Wong HL Eur J Pharm Biopharm; 2012 May; 81(1):24-32. PubMed ID: 22369881 [TBL] [Abstract][Full Text] [Related]
6. Multifunctional peptide-lipid nanocomplexes for efficient targeted delivery of DNA and siRNA into breast cancer cells. Wan Y; Dai W; Nevagi RJ; Toth I; Moyle PM Acta Biomater; 2017 Sep; 59():257-268. PubMed ID: 28655658 [TBL] [Abstract][Full Text] [Related]
7. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy. Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519 [TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid-modified DOTAP/DOPE liposomes for the targeted delivery of anti-telomerase siRNA to CD44-expressing lung cancer cells. Taetz S; Bochot A; Surace C; Arpicco S; Renoir JM; Schaefer UF; Marsaud V; Kerdine-Roemer S; Lehr CM; Fattal E Oligonucleotides; 2009 Jun; 19(2):103-16. PubMed ID: 19374532 [TBL] [Abstract][Full Text] [Related]
9. DOTAP functionalizing single-walled carbon nanotubes as non-viral vectors for efficient intracellular siRNA delivery. Li H; Hao Y; Wang N; Wang L; Jia S; Wang Y; Yang L; Zhang Y; Zhang Z Drug Deliv; 2016; 23(3):840-8. PubMed ID: 24892622 [TBL] [Abstract][Full Text] [Related]
10. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350 [TBL] [Abstract][Full Text] [Related]
11. The effect of siRNA-Egr-1 and camptothecin on growth and chemosensitivity of breast cancer cell lines. Parra E; Ferreira J Oncol Rep; 2010 Apr; 23(4):1159-65. PubMed ID: 20204305 [TBL] [Abstract][Full Text] [Related]
12. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcyclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy. Ran R; Liu Y; Gao H; Kuang Q; Zhang Q; Tang J; Fu H; Zhang Z; He Q J Pharm Sci; 2015 Feb; 104(2):476-84. PubMed ID: 25256603 [TBL] [Abstract][Full Text] [Related]
13. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect. Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812 [No Abstract] [Full Text] [Related]
14. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968 [TBL] [Abstract][Full Text] [Related]
15. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer. Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717 [TBL] [Abstract][Full Text] [Related]
16. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257 [TBL] [Abstract][Full Text] [Related]
17. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF. Şalva E; Turan SÖ; Eren F; Akbuğa J Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537 [TBL] [Abstract][Full Text] [Related]
18. Optimal combination of cationic lipid and phospholipid in cationic liposomes for gene knockdown in breast cancer cells and mouse lung using siRNA lipoplexes. Hattori Y; Tang M; Torii S; Tomita K; Sagawa A; Inoue N; Yamagishi R; Ozaki KI Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35686555 [TBL] [Abstract][Full Text] [Related]
19. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. Wang J; Lu Z; Wang J; Cui M; Yeung BZ; Cole DJ; Wientjes MG; Au JL J Control Release; 2015 Oct; 216():103-10. PubMed ID: 26272765 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic targeting of siRNA/anti-cancer drug delivery system for non-melanoma skin cancer. Part I: Development and gene silencing of JAK1siRNA/5-FU loaded liposome nanocomplexes. Aslan M; Ozturk S; Shahbazi R; Bozdemir Ö; Dilara Zeybek N; Vargel İ; Eroğlu İ; Ulubayram K Eur J Pharm Biopharm; 2024 Oct; 203():114432. PubMed ID: 39097115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]